TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.18) by 20.88 percent. This is a 56.86 percent increase over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $20.197 million which missed the analyst consensus estimate of $20.680 million by 2.34 percent. This is a 25.52 percent increase over sales of $16.091 million the same period last year.